| Prefix | Target | Source | Suffix | ||
|---|---|---|---|---|---|
| variable | -vi(r)- | viral | -u- | human | -mab |
| -ba(c)- | bacterial | -o- | mouse | ||
| -li(m)- | immune system | -a- | rat | ||
| -le(s)- | infectious lesions | -e- | hamster | ||
| -ci(r)- | cardiovascular | -i- | primate | ||
| -fu(ng)- | fungal | -xi- | chimeric | ||
| -ne(r)- | nervous system | -zu- | humanized | ||
| -ki(n)- | interleukin as target | -axo- | rat/murine hybrid | ||
| -mu(l)- | musculoskeletal | -xizu- | chimeric + humanized | ||
| -o(s)- | bone | ||||
| -tox(a)- | toxin as target | ||||
| -co(l)- | colonic tumor | ||||
| -me(l)- | melanoma | ||||
| -ma(r)- | mammary tumor | ||||
| -go(t)- | testicular tumor | ||||
| -go(v)- | ovarian tumor | ||||
| -pr(o)- | prostate tumor | ||||
| -tu(m)- | miscellaneous tumor | ||||
The nomenclature of monoclonal antibodies is a naming scheme for assigning generic, or nonproprietary, names to a group of medicines called monoclonal antibodies. This scheme is used for both the World Health Organization’s International Nonproprietary Names and the United States Adopted Names.[2][1] In general, suffixes are used to identify a class of medicines; all monoclonal antibody pharmaceuticals end with the suffix -mab. However, different preceding suffixes are used depending on the structure and function of the medicine.
Contents |
Components
Infix for origin/source
The infix preceding the -mab suffix denotes the animal origin of the antibodies.[1] Although the original monoclonal antibodies were produced in mice (infix -o-), these antibodies are recognized as foreign by human immune systems and may be rapidly cleared, provoke an allergic reaction, or both. Therefore, parts of the antibody may be replaced with human sequences. If the constant region is replaced with the human form, it is termed chimeric and the affix used is -xi-. Part of the variable regions may also be substituted, in which case it is termed humanized and the infix used is -zu-. Antibodies originating in humans use -u-.
Infix for target
The infix preceding the source of the antibodies refers to medicine’s target. Most of these consist of a consonant, vowel, then another consonant. For ease of pronunciation and to avoid awkwardness, the final consonant is dropped if the following infix begins with a consonant (such as -zu- or -xi-). Examples of these include -ci(r)- for the circulatory system and -tu(m)- for miscellaneous tumors (cancers).[1]
Prefix and second word
Finally, the prefix carries no special meaning and should be unique for each medicine. A second word may be added if there is another substance attached or linked.
Examples
Abciximab is a commonly used medication to prevent platelets from clumping together. It can be broken down into ab- + -ci(r)- + -xi- + -mab. Therefore, it is a chimeric monoclonal antibody used on the cardiovascular system.
Another example is the breast cancer medication trastuzumab, which can be broken down into tras- + -tu(m)- + -zu- + -mab. Therefore, it is a humanized monoclonal antibody used against a tumor.
Bapineuzumab is directed against the beta-amyloid plaques present in the central nervous system of Alzheimer's disease patients.
Adalimumab is a drug targeting TNF alpha. When broken down into ada- + -lim- + -u- + -mab, this compound is a human monoclonal antibody, of human source, targeting the immune system.
See also
References
- ^ a b c d "AMA (USAN) Monoclonal antibodies". United States Adopted Names. 2007-08-07. http://www.ama-assn.org/ama/pub/about-ama/our-people/coalitions-consortiums/united-states-adopted-names-council/naming-guidelines/naming-biologics/monoclonal-antibodies.shtml. Retrieved 2007-08-15.
- ^ "Guidelines on the Use of International Nonproprietary Names (INNs) for Pharmaceutical Substances" (PDF). 1997. pp. 27–28. http://whqlibdoc.who.int/hq/1997/WHO_PHARM_S_NOM_1570.pdf. Retrieved 2007-08-15.
This entry is from Wikipedia, the leading user-contributed encyclopedia. It may not have been reviewed by professional editors (see full disclaimer)
